@EASLedu @EASLnews a fond farewell to all from one of my favorite Paris landmarks. #ilc2018 was a tremendous success. Hope to see you @AASLDtweets #LiverMtg18 in San Francisco in the fall and #ilc2019 in Vienna next year

@EASLedu @EASLnews last day of #ilc2018 promises to have many highlights including EASL guidelines on #HEV and DILI as well as joint #EASL- #ESMO symposium on #HCC

@EASLedu my conclusions after #SORAMIC, SARAH and SIRVENIB: there is no benefit of adding #SIRT to #sorafenib in advanced #HCC #ILC2018

@EASLedu @EASLnews Dr RIcke: #SORAMIC #HCC RCT study of #SIRT+ #sorafenib vs. sorafenib fraught with protocol violations But basically shows no difference in OS #ILC2018

@EASLedu @EASLnews JNJ-6379 #HBV capsid assembly modulator (CAM) drops HBV DNA by 2.2 log. Again, good but whether this is going to be part of the functional cure secret sauce is unclear #ilc2018

@EASLedu @EASLedu Dr. Game: #HBV core protein allosteric modulator #RO7049389 shows 2.7 log HBVDNA Decline at d 28. Well tolerated. one of the ingredients of functional cure? Time will tell. #ilc2018

@EASLedu Dr chalasani: Galectin-3 inhibitor GR-MD-02 fails to meet 54 week primary endpoint of HVPG change in compensated #NASH cirrhosis RCT. The #NASH carnage continues at #ILC2018

@EASLedu Dr Faivre favors biopsies in unresectable #HCC @bruixj @BCLC_group clarifies that this may not be needed for diagnosis in most patients but certainly advances the research field #ILc2018

@EASLedu Dr Faivre: 16-20 % uHCC patients have a durable, significant response to IO therapies. PD-L1 expression status doesn’t seem to matter #ILC2018

@EASLedu Not a big fan of snapping slide pics but this is a nice summary of our treatment arsenal within the next 12-18 months #ilc2018

@EASLedu Dr reig: what is the best 2nd line #HCC option? It depends! #sorafenib tolerance, hepatitis infected or not, treatment history...all factor into this. #ilc2018

@EASLedu @EASLnews Dr. Reig @BCLC_group gives a great review of approved and upcoming #HCC systemic therapies including #nexavar #lenvima #cabometyx #stivarga #opdivo #keytruda #cyramza #ILC2018

Interesting heterogenous responses #ilc2018 @EASLedu

@EASLedu @EASLnews Dr RIcke reviews locoregional therapies and alludes that SARAH and SIRVENIB RCTs which showed no OS benefit of SIRT vs. #sorafenib are flawed. This assertion flies in the face of overwhelming evidence imo #ILC2018

@EASLedu #HCC treatment session: “stage migration” becoming increasingly relevant as systemic therapies improve and the limitations of LRT emerge #ilc2018

@EASLnews juggling bringing along a 5 month old and recreating my parents Parisian honeymoon on its 50th anniversary ...oh and also #ILC2018 exhausting but a lifetime of memories. Merci Paris!

@EASLedu Dr Schwarzkopf: more date to support a beneficial effect of antiplatelet therapy on fibrosis in persons with NAFLD #ILC2018

@EASLedu Dr Nguyen: intragastric balloon results in wt loss and not much else in persons with fatty liver disease #ilc2018

@EASLedu Dr. Alazawi: EMR data for 18 million Europeans (with a lot of assumptions and missing data) suggest about 1% have NAFLD. This could mean that people are grossly underdiagnosing or that the conclusion is grossly erroneous #ILC2018

@EASLedu @EASLnews Dr. Harrison: 2 may not be better than 1 when it comes to #selonsertib + ACC or FXR for 12 weeks in #NASH Side effects on the other hand might add up #ilc2018

@EASLedu @EASLnews Pr. Fournier: All elastography devices seem equally reliable and accurate in assessing fibrosis in NAFLD. My US experience has been suboptimal with elastography in Fatty Liver and excellent with other diseases #ilc2018

How do you assess liver fibrosis in NASH? #ilc2018 @EASLedu

@EASLedu @EASLnews as @Duke_liverdoc highlights, though we may try, there will not be effective high risk screening of fatty liver patients without a disease biomarker #ILC2018

@EASLnews @EASLedu @Duke_liverdoc @Duke_GI_ : huge knowledge gap among broad medical community of what is NASH and how to diagnose it. #ILC2018

@EASLedu Dr Kolly: EASL guidelines do not endorse imaging criteria for diagnosis of #HCC in NON cirrhotic liver and instead recommend biopsy of all suspicious nodules. #ilc2018

@EASLedu @EASLnews Reflecting on failed NASH trials: for the field to advance we need to ditch “steatohepatitis” and focus on the only thing that matters: steatofibrosis #ilc2018

@EASLedu @EASLnews Prof Bosch: cirrhosis is a dynamic potential reversible process. Better nomenclature is ACLD (advanced chronic liver disease) #ilc2018

@EASLnews @EASLedu Prof. Bosch: procoagulant impact of cirrhosis may accelerate decompensation and evidence enoxaparin may delay. Routine application not for the faint of heart. #ilc2018

@EASLnews @EASLedu Prof. Bosch: lifestyle wt loss intervention proven to reduce portal hypertension (HVPG) and adopted by Baveno guidelines. #ilc2018

@EASLedu @EASLnews the indomitable Jaime Bosch delivers a masterful Benhamou state of the art lecture on the theme: is it time to abandon the term cirrhosis? #ilc2018